AHNAK2 upregulated and promoted tumor progression in multiple cancers, such as melanoma, renal clear cell carcinoma, thyroid cancer, and pancreatic ductal carcinoma [13–16]. Here, AHNAK2 is linked to pancreatic ductal adenocarcinoma.